|
Today's Headlines
FDA has approved pomalidomide (Pomalyst, Celgene) to treat patients who have received at least 2 prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
» Full article
|
|
FDA issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of overt dementia. » Full article
|
|
Despite availability of many therapies indicated for bowel disorders, there is still an unmet need and heterogeneity among these patients, necessitating availability of a wide variety of therapeutics. Awareness of potential new products, their key benefits, and where they may fit into the treatment paradigm will be important when making decisions impacting patients and physicians, according to new analysis. » Full article
|
|
Vitamin D supplementation does not slow progression of knee osteoarthritis or reduce pain associated with the condition, according to a study published recently in the Journal of the American Medical Association. » Full article
|
|
ADVERTISEMENT
Save on Rx after Brand-Generic Maxed -
 Download Savings Calculator
Health care payers attempting to reduce Rx spending may have exhausted their potential to switch members from brand to generic. One solution is to move members from their current brand drugs to less expensive alternative brands with equivalent therapeutic intent. Calculate potential savings here.
|
|
CONTINUING EDUCATION
Welcome to the sixth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The February activity covers psychosocial considerations in the management of diabetes.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
A look at the statin prescription trends in the Advocate Physician Partners physician-hospital organization located in northern Illinois. » Full article
|
|
SURVEY
What tops your priority list
for 2013?
– Medication therapy management
– Pharmacy support for new models of care
– Specialty pharmacy management
– Advanced IT support to drive enhanced pharmacy programming
Respond Here
See what your colleagues are saying!
|
|
Like
Tweet
